Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Biol Psychiatry. 2010 Jun 1;67(11):1110-3. doi: 10.1016/j.biopsych.2009.12.010. Epub 2010 Jan 27.
Recent studies have identified associations of polymorphisms in several target genes with antidepressant treatment response of serotonin reuptake inhibitors and a tricyclic antidepressant. We sought to replicate these associations in a study of a serotonin-norepinephrine reuptake inhibitor.
In 250 outpatients with nonpsychotic major depressive disorder, response to treatment with once-daily duloxetine (60 mg/day) over 6 weeks was examined for associations with polymorphisms in eight candidate genes previously associated with antidepressant response using mixed-effect model repeated-measures analysis. Treatment response was quantified on the basis of changes from baseline using 17-item Hamilton Depression Rating Scale total scores.
Polymorphisms in PDE1A, PDE1C, PDE6A, PDE11A, ABCB1, GRIK4, SLC6A4, and OPRM1 genes showed no statistically significant associations (uncorrected, two-tailed p > .05) with duloxetine treatment response.
Previously, described associations between polymorphisms in candidate genes and antidepressant treatment response were not replicated in this study. This result may suggest that previous associations are specific to serotonin reuptake inhibitors.
最近的研究已经确定了几种靶基因的多态性与选择性 5-羟色胺再摄取抑制剂和三环类抗抑郁药的抗抑郁治疗反应之间的关联。我们试图在一项对 5-羟色胺-去甲肾上腺素再摄取抑制剂的研究中复制这些关联。
在 250 名非精神病性重度抑郁症的门诊患者中,使用混合效应模型重复测量分析,检查与之前与抗抑郁反应相关的 8 个候选基因中的多态性与每日一次服用度洛西汀(60mg/天)治疗 6 周的反应之间的关联。治疗反应根据 17 项汉密尔顿抑郁评定量表总分从基线的变化来量化。
PDE1A、PDE1C、PDE6A、PDE11A、ABCB1、GRIK4、SLC6A4 和 OPRM1 基因的多态性与度洛西汀治疗反应无统计学显著关联(未校正,双侧 p>.05)。
本研究未复制先前描述的候选基因多态性与抗抑郁治疗反应之间的关联。这一结果可能表明,之前的关联是特定于选择性 5-羟色胺再摄取抑制剂的。